Catalog No.
AHJ04401
Biological activity
Measured by its binding ability in a functional ELISA. When recombinant human NCR3LG1/B7-H6 (Cat #: AHJ04401) is immobilized at 1 µg/mL (100 µL/well), the concentration of recombinant human NKp30/NCR3 that produces 50% of the optimal binding response is 0.02-0.1 μg/mL.
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Asp25-Ser262
Nature
Recombinant
Endotoxin level
<0.1 EU/μg of the protein by the LAL method.
Purity
>90% as determined by SDS-PAGE.
Accession
Q68D85
Applications
Bioactivity, ELISA, Immunogen, SDS-PAGE, WB
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 5% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
B7H6, NCR3LG1, B7-H6, Natural cytotoxicity triggering receptor 3 ligand 1, B7 homolog 6
Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies., PMID:39408655
A novel NKp80-based strategy for universal identification of normal, reactive and tumor/clonal natural killer-cells in blood., PMID:39040115
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance., PMID:38701193
Analysis of a new therapeutic target and construction of a prognostic model for breast cancer based on ferroptosis genes., PMID:37643511
The potential of B7-H6 as a therapeutic target in cancer immunotherapy., PMID:35697295
Pairs of Mutually Compensatory Frameshifting Mutations Contribute to Protein Evolution., PMID:35137193
The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment., PMID:34639059
NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment., PMID:34594326
Sevoflurane impedes glioma progression via regulating circ_0000215/miR-1200/NCR3LG1 axis., PMID:34460046
B7-H6 as a Diagnostic Biomarker for Cervical Squamous Cell Carcinoma., PMID:34280008
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells., PMID:34253920
Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30., PMID:34046711
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC., PMID:33839362
Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer., PMID:33824367
Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia., PMID:33796404
Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles., PMID:33671836
NCR3LG1 (B7-H6) is a potential prognostic factor for bladder cancer patients., PMID:33523715
Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy., PMID:33483421
Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement., PMID:33268483
Dual role of B7-H6 as a novel prognostic marker in hepatocellular carcinoma., PMID:33220098
B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines., PMID:33172426
B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells., PMID:32770284
Immune Landscape of the B7 and TNFR Families in Oral Squamous Cell Carcinoma., PMID:32548602
Preferential Expression of B7-H6 in Glioma Stem-Like Cells Enhances Tumor Cell Proliferation via the c-Myc/RNMT Axis., PMID:32322592
Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer., PMID:32138659
Genome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ., PMID:31921143
Immunological role and underlying mechanisms of B7-H6 in tumorigenesis., PMID:31904350
The integrated stress response promotes B7H6 expression., PMID:31838577
The prognostic value of B7-H6 in esophageal squamous cell carcinoma., PMID:31792298
Alterations of the Immunologic Co-Stimulator B7 and TNFR Families Correlate with Hepatocellular Carcinoma Prognosis and Metastasis by Inactivating STAT3., PMID:30609841
miR-195/miR-497 Regulate CD274 Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer., PMID:30607158
B7H6 is a functional ligand for NKp30 in rat and cattle and determines NKp30 reactivity toward human cancer cell lines., PMID:30512185
B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape., PMID:30325780
Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition., PMID:30094100
Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer., PMID:29963127
B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas., PMID:29679856
T-bet promotes potent antitumor activity of CD4+ CAR T cells., PMID:29515240
Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies., PMID:29476010
Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression., PMID:29453518
Identification of potential genetic causal variants for rheumatoid arthritis by whole-exome sequencing., PMID:29340042
The B7 Family Member B7-H6: a New Bane of Tumor., PMID:29086181
Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy., PMID:29055565
Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6., PMID:29040754
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis., PMID:28928446
Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20., PMID:28819195
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib., PMID:28576831
The prognostic value of B7-H6 protein expression in human oral squamous cell carcinoma., PMID:28437013
High expression of B7-H6 in human glioma tissues promotes tumor progression., PMID:28415577
Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30., PMID:27663271
B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells., PMID:27216712
For research use only. Not for human or drug use.
